Blocking of beta-2 adrenergic receptors hastens recovery from hypoglycemia-associated social withdrawal

Psychoneuroendocrinology

Volumn 33, Issue 10, 2008, Pages 1411-1418

  Park, Min Jung ^a   Guest, Christopher B ^a   Barnes, Meredith B ^a   Martin, Jonathan ^a   Ahmad, Uzma ^a   York, Jason M ^a   Freund, Gregory G ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

Beta 2 adrenergic receptor; Catecholamines; Hypoglycemia; Insulin treatment; Social withdrawal

Indexed keywords

ADRENALIN; BUTOXAMINE; CATECHOLAMINE; GLUCOSE; INSULIN; NORADRENALIN; RECOMBINANT HUMAN INSULIN; TERBUTALINE;

ADRENALIN BLOOD LEVEL; ANIMAL EXPERIMENT; ARTICLE; CATECHOLAMINE BLOOD LEVEL; CONTROLLED STUDY; DISEASE ASSOCIATION; GLUCOSE BLOOD LEVEL; HYPOGLYCEMIA; MALE; MOUSE; NONHUMAN; NORADRENALIN BLOOD LEVEL; PRIORITY JOURNAL; PSYCHOSOCIAL WITHDRAWAL;

ADRENERGIC ALPHA-AGONISTS; ADRENERGIC BETA-AGONISTS; ADRENERGIC BETA-ANTAGONISTS; ANIMALS; BLOOD GLUCOSE; BUTOXAMINE; EPINEPHRINE; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MICE; MICE, INBRED C57BL; NOREPINEPHRINE; RECEPTORS, ADRENERGIC, BETA-2; SOCIAL BEHAVIOR DISORDERS; TERBUTALINE;

EID: 56249132435     PISSN: 03064530     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2008.08.005     Document Type: Article

References (46)

1. Agardh C.D., and Rosen I. Neurophysiological recovery after hypoglycemic coma in the rat: correlation with cerebral metabolism. J. Cereb. Blood Flow Metab. 3 (1983) 78-85
2. Anisman H., and Sklar L.S. Catecholamine depletion in mice upon reexposure to stress: mediation of the escape deficits produced by inescapable shock. J. Comp. Physiol. Psychol. 93 (1979) 610-625
3. Binder C., and Bendtson I. Endocrine emergencies. Hypoglycaemia. Baillieres Clin. Endocrinol. Metab. 6 (1992) 23-39
4. Bolli G.B. Hypoglycaemia unawareness. Diabetes Metab. 23 Suppl. 3 (1997) 29-35
5. Brown R.J., Sinaii N., and Rother K.I. Too much glucagon, too little insulin: time course of pancreatic islet dysfunction in new-onset type 1 diabetes. Diabetes Care 31 (2008) 1403-1404
6. Cryer P.E. Hypoglycemia. In: Fauci A.S., Braunwald E., Kasper D.L., Hauser S.L., Longo D.L., Jameson J.L., and Loscalzo J.L. (Eds). Harrisons Principles of Internal Medicine (2008), McGraw-Hill 2305-2309
7. Daneman D. Type 1 diabetes. Lancet 367 (2006) 847-858
8. Dantzer R. Cytokine-induced sickness behaviour: a neuroimmune response to activation of innate immunity. Eur. J. Pharmacol. 500 (2004) 399-411
9. Dantzer R., O'Connor J.C., Freund G.G., Johnson R.W., and Kelley K.W. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat. Rev. Neurosci. 9 (2008) 46-56
10. Davis E.A., Keating B., Byrne G.C., Russell M., and Jones T.W. Impact of improved glycaemic control on rates of hypoglycaemia in insulin dependent diabetes mellitus. Arch. Dis. Child. 78 (1998) 111-115
11. Deacon S.P., Karunanayake A., and Barnett D. Acebutolol, atenolol, and propranolol and metabolic responses to acute hypoglycaemia in diabetics. Br. Med. J. 2 (1977) 1255-1257
12. Delamater, A.M., 2006. ISPAD clinical practice consensus guidelines 2006-2007 psychological care of children and adolescents with diabetes.
13. Delamater A.M. Psychological care of children and adolescents with diabetes. Pediatr. Diabetes 8 (2007) 340-348
14. Feingold K.R. Hypoglycemia-a major risk of insulin therapy. West. J. Med. 154 (1991) 469-471
15. Frier B.M. Morbidity of hypoglycemia in type 1 diabetes. Diabetes Res. Clin. Pract. 65 Suppl. 1 (2004) S47-52
16. Gold A.E., Deary I.J., and Frier B.M. Hypoglycemia and cognitive function. Diabetes Care 16 (1993) 958-959
17. Gold A.E., MacLeod K.M., Frier B.M., and Deary I.J. Changes in mood during acute hypoglycemia in healthy participants. J. Pers. Soc. Psychol. 68 (1995) 498-504
18. Gold A.E., Deary I.J., and Frier B.M. Hypoglycaemia and non-cognitive aspects of psychological function in insulin-dependent (type 1) diabetes mellitus (IDDM). Diabet. Med. 14 (1997) 111-118
19. Hartman M.E., O'Connor J.C., Godbout J.P., Minor K.D., Mazzocco V.R., and Freund G.G. Insulin receptor substrate-2-dependent interleukin-4 signaling in macrophages is impaired in two models of type 2 diabetes mellitus. J. Biol. Chem. 279 (2004) 28045-28050
20. Hislop A.L., Fegan P.G., Schlaeppi M.J., Duck M., and Yeap B.B. Prevalence and associations of psychological distress in young adults with type 1 diabetes. Diabet. Med. 25 (2008) 91-96
21. Hoffman R.P., Sinkey C.A., and Anderson E.A. Hypoglycemic symptom variation is related to epinephrine and not peripheral muscle sympathetic nerve response. J. Diabetes Complications 11 (1997) 15-20
22. Hoffman R.P. Sympathetic mechanisms of hypoglycemic counterregulation. Curr. Diabetes Rev. 3 (2007) 185-193
23. Ito T., Fujimura N., Omote K., and Namiki A. A selective beta2-adrenergic agonist, terbutaline, improves sepsis-induced diaphragmatic dysfunction in the rat. Life Sci. 79 (2006) 905-912
24. Johnson D.R., O'Connor J.C., Dantzer R., and Freund G.G. Inhibition of vagally mediated immune-to-brain signaling by vanadyl sulfate speeds recovery from sickness. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 15184-15189
25. Junker V., Becker A., Hühne R., Zembatov M., Ravati A., Culmsee C., and Krieglstein J. Stimulation of beta-adrenoceptors activates astrocytes and provides neuroprotection. Eur. J. Pharmacol. 446 (2002) 25-36
26. Kaan S.K., Mei Q.B., and Cho C.H. A mechanistic study of beta-adrenoceptor antagonists on ethanol-induced gastric damage. Eur. J. Pharmacol. 317 (1996) 115-122
27. Korytkowski M.T., Mokan M., Veneman T.F., Mitrakou A., Cryer P.E., and Gerich J.E. Reduced beta-adrenergic sensitivity in patients with type 1 diabetes and hypoglycemia unawareness. Diabetes Care 21 (1998) 1939-1943
28. Levin B.E. Neuronal glucose sensing: still a physiological orphan?. Cell Metab. 6 (2007) 252-254
29. Lin K.I., Johnson D.R., and Freund G.G. LPS-dependent suppression of social exploration is augmented in type 1 diabetic mice. Brain Behav. Immun. 21 (2007) 775-782
30. Lustman P.J., and Clouse R.E. Depression in diabetes: the chicken or the egg?. Psychosom. Med. 69 (2007) 297-299
31. Martelli A., Allavena A., Campart G.B., Canonero R., Ghia M., Mattioli F., Mereto E., Robbiano L., and Brambilla G. In vitro and in vivo testing of hydralazine genotoxicity. J. Pharmacol. Exp. Ther. 273 (1995) 113-120
32. Marvel F.A., Chen C.C., Badr N., Gaykema R.P., and Goehler L.E. Reversible inactivation of the dorsal vagal complex blocks lipopolysaccharide-induced social withdrawal and c-fos expression in central autonomic nuclei. Brain Behav. Immun. 18 (2004) 123-134
33. McAulay V., Deary I.J., Sommerfield A.J., Matthews G., and Frier B.M. Effects of acute hypoglycemia on motivation and cognitive interference in people with type 1 diabetes. J. Clin. Psychopharmacol. 26 (2006) 143-151
34. Northam E.A., Anderson P.J., Jacobs R., Hughes M., Warne G.L., and Werther G.A. Neuropsychological profiles of children with type 1 diabetes 6 years after disease onset. Diabetes Care 24 (2001) 1541-1546
35. Podojil J.R., Kin N.W., and Sanders V.M. CD86 and beta2-adrenergic receptor signaling pathways, respectively, increase Oct-2 and OCA-B expression and binding to the 3′-IgH enhancer in B cells. J. Biol. Chem. 279 (2004) 23394-23404
36. Pratley R.E., and Salsali A. Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes. Curr. Med. Res. Opin. 23 (2007) 919-931
37. Ragozzino M.E., Adams S., and Kesner R.P. Differential involvement of the dorsal anterior cingulate and prelimbic-infralimbic areas of the rodent prefrontal cortex in spatial working memory. Behav. Neurosci. 112 (1998) 293-303
38. Rao J., Oz G., and Seaquist E.R. Regulation of cerebral glucose metabolism. Minerva. Endocrinol. 31 (2006) 149-158
39. Service F.J. Hypoglycemic disorders. N. Engl. J. Med. 332 (1995) 1144-1152
40. Shalitin S., and Phillip M. The role of new technologies in treating children and adolescents with type 1 diabetes mellitus. Pediatr. Diabetes 8 Suppl. 6 (2007) 72-79
41. Sherry C.L., O'Connor J.C., Kramer J.M., and Freund G.G. Augmented lipopolysaccharide-induced TNF-alpha production by peritoneal macrophages in type 2 diabetic mice is dependent on elevated glucose and requires p38 MAPK. J. Immunol. 178 (2007) 663-670
42. Silverstein J., Klingensmith G., Copeland K., Plotnick L., Kaufman F., Laffel L., Deeb L., Grey M., Anderson B., Holzmeister L.A., and Clark N. American Diabetes Association: care of children and adolescents with type 1 diabetes: a statement of the American Diabetes Association. Diabetes Care 28 (2005) 186-212
43. Ste Marie L., and Palmiter R.D. Norepinephrine and epinephrine-deficient mice are hyperinsulinemic and have lower blood glucose. Endocrinology 144 (2003) 4427-4432
44. Thaker P.H., Han L.Y., Kamat A.A., Arevalo J.M., Takahashi R., Lu C., Jennings N.B., Armaiz-Pena G., Bankson J.A., Ravoori M., Merritt W.M., Lin Y.G., Mangala L.S., Kim T.J., Coleman R.L., Landen C.N., Li Y., Felix E., Sanguino A.M., Newman R.A., Lloyd M., Gershenson D.M., Kundra V., Lopez-Berestein G., Lutgendorf S.K., Cole S.W., and Sood A.K. Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat. Med. 12 (2006) 939-944
45. Weiss J.M., Glazer H.I., Pohorecky L.A., Brick J., and Miller N.E. Effects of chronic exposure to stressors on avoidance-escape behavior and on brain norepinephrine. Psychosom. Med. 37 (1975) 522-534
46. Westfall T.C., and Westfall D.P. Adrenergic agonists and antagonists. In: Brunton L.L., Lazo J.S., and Parker K.L. (Eds). Goodman & Gilman's the Pharmacological Basis of Therapeutics (2005), McGraw-Hill 237-295